PI4KA inhibitor-F1 structure
|
Common Name | PI4KA inhibitor-F1 | ||
|---|---|---|---|---|
| CAS Number | 1402345-92-9 | Molecular Weight | 603.52 | |
| Density | 1.6±0.1 g/cm3 | Boiling Point | 744.3±70.0 °C at 760 mmHg | |
| Molecular Formula | C27H18F5N5O4S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | 404.0±35.7 °C | |
Use of PI4KA inhibitor-F1GSK-F1 (Compound F1) is an orally active PI4KA inhibitor with pIC50 values of 8.0, 5.9, 5.8, 5.9, 5.9 and 6.4 against PI4KA, PI4KB, PI3KA, PI3KB, PI3KG and PI3KD, respectively. GSK-F1 can be used for HCV infection research[1]. |
| Name | 5-{2-Amino-4-oxo-3-[2-(trifluoromethyl)phenyl]-3,4-dihydro-6-quinazolinyl}-N-(2,4-difluorophenyl)-2-methoxy-3-pyridinesulfonamide |
|---|---|
| Synonym | More Synonyms |
| Description | GSK-F1 (Compound F1) is an orally active PI4KA inhibitor with pIC50 values of 8.0, 5.9, 5.8, 5.9, 5.9 and 6.4 against PI4KA, PI4KB, PI3KA, PI3KB, PI3KG and PI3KD, respectively. GSK-F1 can be used for HCV infection research[1]. |
|---|---|
| Related Catalog | |
| Target |
PI4KA:8.0 (pIC50) PI4KB:5.9 (pIC50) PI3KA:5.8 (pIC50) PI3KB:5.9 (pIC50) PI3KG:5.9 (pIC50) PI3KD:6.4 (pIC50) |
| References |
| Density | 1.6±0.1 g/cm3 |
|---|---|
| Boiling Point | 744.3±70.0 °C at 760 mmHg |
| Molecular Formula | C27H18F5N5O4S |
| Molecular Weight | 603.52 |
| Flash Point | 404.0±35.7 °C |
| Exact Mass | 603.099976 |
| LogP | 4.43 |
| Vapour Pressure | 0.0±2.5 mmHg at 25°C |
| Index of Refraction | 1.646 |
| InChIKey | MSRFVAYVUUHQCN-UHFFFAOYSA-N |
| SMILES | COc1ncc(-c2ccc3nc(N)n(-c4ccccc4C(F)(F)F)c(=O)c3c2)cc1S(=O)(=O)Nc1ccc(F)cc1F |
| Storage condition | -20°C |
| Hazard Codes | Xn |
|---|
| 3-Pyridinesulfonamide, 5-[2-amino-3,4-dihydro-4-oxo-3-[2-(trifluoromethyl)phenyl]-6-quinazolinyl]-N-(2,4-difluorophenyl)-2-methoxy- |
| 5-{2-Amino-4-oxo-3-[2-(trifluoromethyl)phenyl]-3,4-dihydro-6-quinazolinyl}-N-(2,4-difluorophenyl)-2-methoxy-3-pyridinesulfonamide |
| PI4KA inhibitor-F1 |